Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Roche’s risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy
Roche’s risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy
Basel, 11 November 2019 – Roche (SIX.
AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat in P-III Program for CKD Patients with Anaemia
AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat in P-III Program for CKD Patients with Anaemia
The P-III program involves assessing of Roxadustat vs PBO and epoetin alfa in 9,000+ NDD and DD & ID patients in multiple studies conducted by AstraZeneca, FibroGen and Astellas together globa...
Vaccine against Ebola: Commission grants first-ever market authorisation
Vaccine against Ebola: Commission grants first-ever market authorisation
Today, the European Commission adopted the decision granting marketing authorisation to the company Merck Sharp & Dohme B.
FDA Grants Priority Review to Opdivo-Yervoy Combo in Advanced HCC
FDA Grants Priority Review to Opdivo-Yervoy Combo in Advanced HCC
The FDA has accepted the supplemental biologics license application and granted breakthrough therapy designation to nivolumab (Opdivo) plus ipilimumab (Yervoy) for the treatment of pat...
Roche Discontinues Trial of Duchenne Muscular Dystrophy Drug RG6206
Roche Discontinues Trial of Duchenne Muscular Dystrophy Drug RG6206
Roche has discontinued a phase 2/3 trial of RG6206 after a futility analysis showed that the drug was “highly unlikely” to demonstrate clinical benefit in patients with Duchenne muscular dystrophy...
Novo Nordisk obtains exclusive worldwide licence to potential NASH candidate UD-014 from UBE Industries
Novo Nordisk obtains exclusive worldwide licence to potential NASH candidate UD-014 from UBE Industries
Novo Nordisk A/S and UBE Industries Ltd.
Brain implants used to fight drug addiction in US
Brain implants used to fight drug addiction in US
Patients with severe opioid addiction are being given brain implants to help reduce their cravings, in the first trial of its kind in the US.
FDA approves first therapy to treat patients with rare blood disorder
FDA approves first therapy to treat patients with rare blood disorder
Today the U.
Britain's AstraZeneca to distribute Sun Pharma cancer drugs in China
Britain's AstraZeneca to distribute Sun Pharma cancer drugs in China
BENGALURU (Reuters) - Top Indian drugmaker Sun Pharmaceutical Industries Ltd said on Wednesday Britain’s AstraZeneca would distribute some of Sun’s cancer treatment drugs in China, the wor...
The Online User Experience That Can Drive Action for Your Brand
The Online User Experience That Can Drive Action for Your Brand
Promoting change is difficult, so it’s empowering to learn that online health information can inspire health-improving actions.
Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S.
Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S.
Already facing the launch of U.
Britain's AstraZeneca launches $1 billion China investment fund with CICC
Britain's AstraZeneca launches $1 billion China investment fund with CICC
SHANGHAI (Reuters) - AstraZeneca (AZN.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand